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Survival extrapolation in the presence of
cause specific hazards
Tatiana Benaglia,a Christopher H. Jacksonb and
Linda D. Sharplesc*†
Health economic evaluations require estimates of expected survival from patients receiving different interven-
tions, often over a lifetime. However, data on the patients of interest are typically only available for amuch shorter
follow-up time, from randomised trials or cohorts. Previous work showed how to use general population mortal-
ity to improve extrapolations of the short-term data, assuming a constant additive or multiplicative effect on the
hazards for all-cause mortality for study patients relative to the general population. Amore plausible assumption
may be a constant effect on the hazard for the specific cause of death targeted by the treatments. To address this
problem, we use independent parametric survival models for cause-specific mortality among the general popu-
lation. Because causes of death are unobserved for the patients of interest, a polyhazard model is used to express
their all-cause mortality as a sum of latent cause-specific hazards. Assuming proportional cause-specific hazards
between the general and study populations then allows us to extrapolate mortality of the patients of interest to
the long term. A Bayesian framework is used to jointly model all sources of data. By simulation, we show that
ignoring cause-specific hazards leads to biased estimates of mean survival when the proportion of deaths due to
the cause of interest changes through time. The methods are applied to an evaluation of implantable cardioverter
defibrillators for the prevention of sudden cardiac death among patients with cardiac arrhythmia. After account-
ing for cause-specific mortality, substantial differences are seen in estimates of life years gained from implantable
cardioverter defibrillators. © 2014 The Authors Statistics in Medicine Published by John Wiley & Sons Ltd.
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1. Introduction
In health economic evaluations, we compare the expected cost and clinical effectiveness associated
with different treatments or other health technologies. In the UK, the organisation responsible for these
appraisals is the National Institute for Health and Clinical Excellence, which recommends whether a new
technology should be given public funding in the presence of a limited budget. An important component
of many health economic evaluations is the effect of the new treatment on the long-term survival or some
functional of it, such as mean survival or life expectancy for the groups of interest. Treatment effects are
usually obtained from RCTs. However, for many chronic diseases, the choice of treatment has an impact
on survival over much longer periods than those covered by the follow-up of trials. Typically, estimates
of expected lifetime survival are required to evaluate each treatment policy, but only a short-term survival
curve is available from the trial.
Assuming that short-term individual-level data are available, the simplest approach to estimating long-
term expected survival is to fit a parametric or semi-parametric survival model to these data, then integrate
the fitted survival curve over a lifetime [1]. This approach is often sensitive to the choice of model [2].
More importantly, extrapolations from even the best-fitting models may be unrealistic if the observed
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period is short compared to the unobserved period. Then it is desirable to include relevant external long-
term data. Survival data for patients with the disease of interest may be available from disease registries
or hospital-based cohorts [1]. These may provide information on longer-term follow-up or older ages
[3], but the follow-up will not always be sufficiently long. Population lifetime survival might be obtained
from national agencies such as the UK Office for National Statistics; however, untestable assumptions
about how the general population survival differs from the extrapolated survival of the patients of interest
are usually necessary. For example, patients who have survived a certain length of time may sometimes
be assumed to be ‘cured’ and have the same survival as the general population [4].
Our motivating example concerns implantable cardioverter defibrillators for the secondary prevention
of cardiac arrhythmia. Connolly et al. [5] present a meta-analysis of RCTs comparing implantable car-
dioverter defibrillators (ICDs) to anti-arrhythmic drugs (AAD). The studies included had around 5 years
of follow-up. To inform policy in a UK context, we combine their published summaries with individual
data from a cohort of UK ICD patients and age-sexmatched national population survival data [available at
http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Interim+Life+Tables]. Demiris and Sharples [6]
described models for estimating expected survival based on these specific datasets. A Bayesian model
with shared parameters was fitted simultaneously to all data sources. Hazards were assumed to be propor-
tional (or additive) between the study populations and the general population. More plausibly, however,
the relationships between the hazards will be different for different causes of death. In polyhazard mod-
els [7], the overall hazard is decomposed as a sum of contributions, interpreted as particular causes of
death, which are not published in the data. Demiris et al. [8] used a poly-Weibull model to extrapo-
late mean survival after transplantation, using a single dataset with reasonably long follow-up, where
high initial surgery-related hazards and increasing long-term mortality results in a ‘bathtub’ or U-shaped
hazard curve.
In this paper, we combine short-term individual-level data on patients of interest with causes of death
unknown, and long-term general population data with causes of death known, to obtain extrapolations of
the expected lifetime of the patients of interest. We assume that the hazard for death from the disease of
interest is proportional, while the hazard for all other causes is identical, between the study patients and
the general population. In Section 2, we present the two-component polyhazard modelling framework
used throughout this paper. Then in Section 3, we perform a simulation study to investigate the biases in
expected survival resulting from assuming that the hazard for all-cause mortality is proportional between
the general population and the study patients (as in [6]) when in reality the relationships among the
hazards are different for different causes of death. Section 4 presents the proposed methodology applied
to the data studied by Demiris and Sharples [6] on the comparison between implantable cardioverter
defibrillators and AAD for cardiac arrhythmia. As well as being proportional between the general and
study population, hazards are also assumed to be proportional between treatment groups within the study
population, although this assumption is also untestable given the limited follow-up of the RCT providing
the treatment effect. Finally, we discuss the findings and limitations of these methods, in particular the
risks of combining data from different sources and the importance of publishing causes of death.
2. Two component polyhazard model
We have two individual-level survival datasets, one from the general population and one from patients
with some disease of interest. Suppose there are two possible causes of death, where the disease group
has an increased hazard of death from the cause of interest k = 1 and identical hazard for other causes
k = 2. In this section, we show how to use the population data to extrapolate the survival of the disease
group. For the moment, we assume the patients of interest all receive the same treatment. In Section 4.3,
we extend this method to a comparison of survival between treatment groups.
2.1. Population data
Assume that for an individual in the general population (superscript p), the distributions of the times to
death Tpk for causes k = 1, 2 come from the same parametric family but with different parameters. For
illustration, here, we use Weibull distributions with shape and rate parameters 𝛼k and 𝜆k, respectively:
Tpk ∼ Weibull(𝛼k, 𝜆k).
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Thus, the hazard is either constant, increasing or decreasing over time if 𝛼k = 1, 𝛼k > 1 or 𝛼k < 1,
respectively. For each individual i in the population data, suppose the cause of death is known, so the
corresponding cause-specific survival time tpik is observed if the individual died from cause k (denoted
𝛿
p
ik = 1) or censored otherwise
(
𝛿
p
ik = 0
)
. The data ypk =
{(
tpik, 𝛿
p
ik
)
∶ i = 1,… , n
}
for k = 1, 2 therefore
contribute the following terms to the likelihood for parameters 𝛼 = (𝛼1, 𝛼2) and 𝜆 = (𝜆1, 𝜆2).
Lpk
(
𝛼, 𝜆|ypk) =
n∏
i=1
Sp
(
tpik|𝛼k, 𝜆k) hp (tpik|𝛼k, 𝜆k)𝛿
p
ik , (1)
where Sp(t|𝛼k, 𝜆k) = exp (−𝜆kt𝛼k) and hp(t|𝛼k, 𝜆k) = 𝜆k𝛼kt𝛼k−1 are the survivor and hazard functions of
the cause-specific Weibull distributions.
2.2. Study data
For patients in the study group, we assume that the other-cause survival distribution is the same as that for
the population, Weibull(𝛼2, 𝜆2). The hazard for the cause of interest, however, is proportionally increased
to reflect their higher risk, with the increase described by the cause-specific log hazard ratio 𝛽 between the
study and population groups. Thus, the survival distribution for the cause of interest isWeibull
(
𝛼1, e
𝛽𝜆1
)
.
The causes of death are not observed in the study data; therefore, we cannot fit independent Weibull
models as in (1). Instead, we use the fact that if there are K competing causes of death with respective
hazard functions h1(t),… , hk(t), then the actual death time follows a polyhazard model [7] with overall
hazard
∑
k hk(t). In this case, k = 1 or 2, and the observed death times in the study data follow a poly-
Weibull distribution with hazard function:
hs(t|𝛼, 𝜆, 𝛽) = e𝛽h1p(t|𝛼1, 𝜆1) + h2p(t|𝛼2, 𝜆2)
= e𝛽𝜆1𝛼1t𝛼1−1 + 𝜆2𝛼2t𝛼2−1.
(2)
The contribution of the study data ys =
{(
tsj , 𝛿
s
j
)
∶ j = 1,… ,m
}
to the overall likelihood is given by
Ls (𝛼, 𝜆, 𝛽|ys) =
n∏
j=1
Ss
(
tsj |𝛼, 𝜆, 𝛽
)
hs
(
tsj |𝛼, 𝜆, 𝛽
)𝛿sj
, (3)
where the survivor function for the poly-Weibull distribution is Ss(t|𝛼, 𝜆, 𝛽) = exp (−e𝛽𝜆1t𝛼1 − 𝜆2t𝛼2).
2.3. Combining population and study data
The overall likelihood for the combined population and study data is then
L
(
𝛼, 𝜆, 𝛽|yp1, yp2, ys) = Ls (𝛼, 𝜆, 𝛽|ys)
2∏
k=1
Lpk
(
𝛼, 𝜆|ypk) . (4)
We estimate the parameters 𝛼, 𝜆, 𝛽 in a Bayesian framework. This allows any previously published infor-
mation about differences between populations to be included as prior distributions on the corresponding
hazard ratio (Section 4.3) and facilitates computation byMCMC in software such as WinBUGS [9]. Dur-
ing the MCMC process, we use samples from the posterior distributions of the parameters to compute
the posterior distribution of the mean survival, or life expectancy of the study patients, defined as the area
under the survival curve:
E(Ts) = ∫
∞
0
Ss(t|𝛼, 𝜆, 𝛽)dt.
Polyhazard models based on various distributions, including the Weibull, were compared by Louzada-
Neto [7]. In applications, the fit of any assumed distribution to the observed data, and its plausibility in
extrapolation, should be checked. An advantage of the Weibull (also shared by the Gompertz distribu-
tion, for example) is its proportional hazards property, which enables differences between populations
to be expressed intuitively as hazard ratios. The potential identifiability problems with the poly-Weibull
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model have been discussed [8]—when fitted to a single survival dataset without cause of death recorded,
the parameters can only be identified if the multiple causes have hazard trajectories that can be easily
distinguished given the overall hazard trajectory. For example, two causes with strictly increasing and
strictly decreasing hazards result in a U-shaped hazard for overall survival. In our case, information on
the cause-specific parameters 𝜆k and 𝛼k is enhanced by the population data y
p
k through the likelihood (4).
In Section 4.3, we explain how to extend this method to also estimate the survival of patients receiving
a different treatment from those in the study data, assuming that a summary treatment effect is available
from literature or further individual data.
3. Simulation
In this section, we perform a simulation study to investigate the potential bias incurred from ignoring a
cause-specific survival effect when extrapolating survival. Estimates obtained by the polyhazard-based
model described in Section 2 are compared with those from two misspecified models, which do not take
into account the cause-specific effect but assume that the study patients have a proportionally increased
hazard for overall survival compared to the general population.
3.1. Design of the simulation study
Censored survival data for hypothetical general and study populations, with assumed age of 60 at time
0, were simulated. We assumed two mutually exclusive causes of death, each with a Weibull survival
distribution, as in Section 2. This implies two-component poly-Weibull distributions for overall survival.
The following factors that could affect the accuracy and precision of the parameter estimates were varied
in the simulations:
(1) The Weibull shape parameters 𝛼 (Table I). Model 1 assumes that the shape parameters for the two
causes of death are the same, equivalent to a Weibull model for overall mortality with hazard equal
to the sum of the component-specific hazards. Models 2 and 3 have a higher shape parameter for
causes other than the disease of interest, suggesting that the proportion of overall mortality due to
the cause of interest decreases through time, and this is particularly rapid in Model 3.
(2) The increase in the cause specific risk for the study group relative to the general population: 𝛽 = 1.5
or 3.
The Weibull parameters and mean survival implied by these six combinations of scenarios are sum-
marised in Table I. Model 2 with 𝛽 = 1.5 approximately reflects the mortality rates in our motivating
application to the UK ICD cohort. For each scenario and simulation replicate, two datasets were gener-
ated, the first with 1000 observations corresponding to times of death for the general population and the
second with times of death for 500 patients from the study cohort. Censoring times were generated from
an exponential distribution, up to 10 years, at which time all surviving patients were censored. The expo-
nential rate was set to 0.15 if 𝛽 = 1.5, or 0.4 if 𝛽 = 3, to give a similar pattern of censoring to the ICD
cohort, where 15% of events were observed by 10 years.
Table I. Weibull distribution parameters governing simulated population and study data under six simula-
tion scenarios, defined by combinations of three Weibull shape specifications and two log (study/population)
hazard ratios 𝛽.
3: Rapidly decreasing
2: Decreasing cause-specific cause-specific relative
Data Parameter 1: Weibull relative hazard hazard
General population 𝛼0 (1.7, 1.7) (1.5, 2) (1.5, 4.5)
(n0 = 1000) 𝜆0 (0.0015, 0.0022) (0.0015, 0.0022) (1.5 × 10−3, 1.5 × 10−7)
Mean 24.04 17.58 26.96
Study group 𝛼 (1.7, 1.7) (1.5, 2) (1.5, 4.5)
(n = 500) 𝜆 (0.0015e𝛽 , 0.0022) (0.0015e𝛽 , 0.0022) (0.003e𝛽 , 0.001)
𝛽 = 1.5 Mean 14.32 14.22 19.78
Study group 𝛼 (1.7, 1.7) (1.5, 2) (1.5, 4.5)
(n = 500) 𝜆 (0.0015e𝛽 , 0.0022) (0.0015e𝛽 , 0.0022) (0.003e𝛽 , 0.001)
𝛽 = 3 Mean 6.72 8.09 9.20
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Figure 1. Hazard functions for data simulated for the population (first row) and study group with 𝛽 = 1.5 (second
row) and 𝛽 = 3 (third row); under models 1 (left), 2 (middle) or 3 (right).
The hazard functions for the models described in the preceding text are presented in Figure 1. The
population data are represented in the top row, while the middle and bottom rows represent the study
data whose cause-specific log hazard ratio 𝛽 compared to the population is 1.5 and 3, respectively. Notice
that in Model 1 (left column), the hazard related to other causes is larger than the hazard of interest
in the general population, but that direction is reversed in the study cohort. In models 2 and 3 (middle
and right columns), the hazard related to the cause of interest is very small in the population data, but
increases in the study cohort at a rate that depends on 𝛽. A characteristic of Model 3, that is plausible for
some situations, is that the hazard for the cause of interest in the study group is higher compared to other
causes for a certain period at the beginning of the study, which represents the time immediately after
presentation, but as the patient gets older, the hazard of dying from other causes becomes predominant.
For each of the six scenarios, we simulated 50 replicate datasets and fitted three different models:
(1) Poly-Weibull (4): this is the true model and assumes a cause specific effect, in that the hazard for
mortality from the disease of interest differs between the study and general populations, but the
hazards for other causes do not.
(2) Weibull model fitted to the combined data, with joint likelihood defined by a product of population
and study likelihoods with common shape 𝛼 and scales 𝜆 and e𝛽𝜆, respectively. Thus, the hazard for
overall mortality is assumed proportional between the study and general population.
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(3) Semi-parametric ‘Cox-like’ model: using a similar joint likelihood with proportional hazards (for
all causes) between the population and the study group. The baseline hazard is a piecewise-constant
function with change points at every observed death time. This model is described in more detail
by Demiris and Sharples [6] and Jackson et al. [2]. Like the standard Cox model, this assumes
proportional hazards while making minimal assumptions about the baseline hazard.
3.2. Prior distributions
We used weakly informative priors corresponding to beliefs expressed on an easily interpretable scale.
For all poly-Weibull and Weibull models, we used Uniform(0,100) priors for the scale (1∕𝜆k or 1∕𝜆).
This expresses the belief that patients cannot survive more than about 60 years after entry to the study
(simulated patients were assumed to be aged 60 at entry)—because even when 𝛼 is at its prior limits, the
impliedmean cause-specific survival time of (1∕𝜆)Γ(1+1∕𝛼) cannot bemore than about 60.We expect the
hazard for both arrhythmia-related death and other causes of death to increase through time. Therefore, we
use weakly informative Normal priors for log(𝛼k) (or log(𝛼)) with a mean of 0.5 and standard deviation of
0.78 = (log(log(100)∕ log(2)+1)−0.5)∕Φ−1(0.975), which implies an expected hazard ratio of 1.5 for a
doubled time since age 60 years, with 95% credible interval approximately between 0.64 and 100. For the
log hazard ratio of mortality from the disease of interest between the general population and the patients
of interest, we use Normal priors with mean 0 and standard deviation of 2.5, which gives a 95% credible
interval for the hazard ratio of between 1/150 and 150. To aid the identifiability of the two components of
the poly-Weibull model, we constrained the scale parameters such that 𝜆1 < 𝜆2, as suggested by Demiris
et al. [8]. For the semi-parametric model, independent Gamma(c𝜇, c) priors were used for the baseline
hazards, as in [6], with c = 200 to ensure a high variance, and the mean 𝜇 set to the true hazard.
The models were fitted using MCMC algorithms in WinBUGS [9], using the WBDev add-on [10] to
implement the poly-Weibull distribution. An example of the WinBUGS code required for these models
is given in Appendix A.
3.3. Results
Tables II and III show, for each of six scenarios, the mean (over simulation replicates) of the posterior
mean expected survival, the corresponding mean absolute (and percentage) bias, and the coverage of the
95% credible intervals.
Table II. Bias and coverage in point and interval estimates of expected survival when 𝛽 = 1.5.
Model True Weibull Cox-like Poly-Weibull
1: Weibull
Mean 14.32 14.31 14.71 14.76
Bias (%) −0.01 (−0.1%) 0.39 (2.7%) 0.44 (3.1%)
Coverage 0.94 0.98 0.96
2: Decreasing cause-specific
Mean 14.22 13.40 13.75 14.16
relative hazard
Bias (%) −0.82 (−5.8%) −0.47 (−3.3%) −0.06 (−0.4%)
Coverage 0.78 0.96 0.72
3: Rapidly decreasing cause-
Mean 19.78 14.19 17.10 19.15
specific relative hazard
Bias (%) −5.62 (−28.4%) −2.68 (−13.5%) −0.63 (−3.20%)
Coverage 0.00 0.80 0.90
Table III. Bias and coverage in point and interval estimates of expected survival when 𝛽 = 3.
Model True Weibull Cox-like Poly-Weibull
1:Weibull
Mean (95% CI) 6.72 6.76 7.11 6.95
Bias (%) 0.04 (0.6%) 0.39 (5.8%) 0.23 (3.40%)
Coverage 0.92 0.96 0.84
2: Decreasing cause-specific
Mean (95% CI) 8.09 7.08 7.78 7.68
relative hazard
Bias (%) −1.01 (−12.5%) −0.31 (−3.8%) −0.41 (−5.1%)
Coverage 0.52 0.96 0.82
3: Rapidly decreasing cause-
Mean (95% CI) 9.20 6.77 9.13 8.71
specific relative hazard
Bias (%) −2.43 (−26.4%) −0.07 (−0.8%) −0.49 (−5.3%)
Coverage 0.00 1.00 0.86
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Figure 2. Posterior means and 95% credible intervals for expected survival under 50 simulation replicates, for
data simulated under three different models and 𝛽 = 1.5. True value shown is in red, and mean of 50 posterior
means is shown in blue.
Independently of the value of 𝛽, when the data are simulated from the Weibull model 1, there is negli-
gible bias and coverage close to the nominal 95% for all fitted models. This is expected, because the true
model has the same shape parameter for both causes of death and thus reduces to a Weibull model for
overall mortality. When the data arise from Models 2 and 3, as the difference between the cause-specific
shape parameters increases, the bias resulting from fitting the Weibull model also increases. This is illus-
trated in Figures 2 and 3, which show the posterior mean and 95% credible interval for expected survival
for each simulation replicate. The red solid horizontal line represents the true value, and the blue dashed
line is the mean (over 50 replicates) of the posterior means. The poly-Weibull model gives the least biased
estimates for 𝛽 = 1.5. For 𝛽 = 3, the Cox-like model also has reasonably low biases— but although the
posterior means of expected survival are not far from the true value, the uncertainty around the estimates
is always bigger compared to the other models, due to the need to estimate a different baseline hazard
for every interval between event times (Figures 2 and 3). This can lead to interval estimates with excess
coverage (e.g., Table III, Model 3), although there is some uncertainty in these estimates of coverage,
due to only performing 50 simulation replicates. Most noticeable is the bias introduced when ignoring
the cause specific effect by assuming a Weibull model. When the contribution of the cause of interest to
overall mortality is rapidly decreasing through time (Model 3), and 𝛽 = 1.5, the Weibull model underes-
timates the mean survival by an average of 5.6 years. Likewise if 𝛽 = 3, mean survival is underestimated
802
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Figure 3. Posterior means and 95% credible intervals for expected survival under 50 simulation replicates, for
data simulated under three different models and 𝛽 = 3. True value shown is in red, and mean of 50 posterior
means is shown in blue.
by almost 3 years. In both cases, this is a bias of the order of 30%, which would often make a substan-
tial difference to policy decisions. In contrast, the biases in the estimates obtained using the Cox-like
model are much lower, with mean survival underestimated by at most 2.68 years. Thus, the flexibility of
the baseline hazards in the Cox model will, to some extent, compensate for the misspecified assumption
of proportional hazards for overall survival to give minimally biased estimates of overall survival. The
price for this is a reduction in efficiency and loss in precision (demonstrated by coverage probability of
1), which may be important if the data set is small.
These results are also illustrated in Figure 4, which compares the true survival curves to a fitted sur-
vival curve for a representative simulation replicate. There is a good fit by all models when the data are
generated from Model 1, whereas the mean survival is underestimated by the Weibull model when the
data are generated from Model 3. The underestimation is particularly evident when survival is extrap-
olated. The pattern for bias in the Cox-like model is less clear in our simulations, reflecting the higher
variance in these estimates.
Our simulation study has focused on the specific case of the use of Weibull and Cox models for over-
all survival when the contribution of the cause-specific risk of interest is decreasing over time, so that
overall survival is correctly modelled by a poly-Weibull distribution. While this study gives an indica-
tion of the patterns of bias and efficiency when estimating mean survival, it does not comprehensively
© 2014 The Authors Statistics in Medicine Published by John Wiley & Sons Ltd Statist. Med. 2015, 34 796–811
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Figure 4. True and fitted survival curves for one simulation replicate, under true models 1, 2, and 3, and 𝛽 = 1.5
(top) or 𝛽 = 3 (bottom)
investigate the degree of bias and efficiency. The study demonstrated that for model 3, in which a doubling
of time relates to a doubling of risk for the rapidly increasing hazard, the frequently used Weibull distri-
bution can result in bias of the order of 30%, while the Cox model will be more accurate (at most 13.5%
bias in our simulations). We note that the extent of bias due to changing risk contribution is primarily
influenced by the shape parameters 𝛼. Detailed examination of these parameters (or analogous parame-
ters in alternative survival functions) is most likely to provide insight into the implications of ignoring
cause-specific hazards. Additionally, the simulation study does not investigate a wide range of possible
survival distributions. For example, the poly-Weibull may give poor estimates of overall survival if the
data were generated according to, say, a poly-Gompertz distribution. Therefore, assessment of model fit to
both short-term and long-term data sources is important, although not all assumptions about extrapolated
parameters can be checked that way, and a more comprehensive simulation study could be worthwhile.
4. Application to implantable cardioverter defibrillators
4.1. Implantable cardioverter defibrillators cohort and population data
The simulation study showed the potential for bias when study group survival is extrapolated by apply-
ing overall instead of cause-specific hazard ratios to population data when the cause of interest is not a
constant proportion of all cause mortality through time. Here, we apply the same models to a study of
ICD in a cohort of patients with cardiac arrhythmia who have survived a ‘sudden cardiac death’ event.
Thus, arrhythmia-related deaths are cause k = 1.
The study data consist of 535 patients implanted with ICDs between 1991 and 2002 (244 and 291
implants from Papworth and Liverpool hospitals, respectively). There were 81 observed deaths, and the
follow-up was at most 10 years post implant, with 75% of the sample having follow-up below 3.5 years.
The empirical survival curve is illustrated in Figure 5 (left). Causes of death were not recorded. The
average age at implant was 60 years, and men represented 81% of this cohort. The empirical hazard
rate fluctuated around an approximately constant value during the observed follow-up period (Figure 5,
right); however, it is unlikely to remain constant in the long term because we expect mortality rates to
increase with age. As in Demiris and Sharples [6], we assume that the distributional family governing
the survival of ICD patients is the same as that of the general population in the UK matched by age and
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Figure 5. Survival curves (left) and log hazards (right) for implantable cardioverter defibrillators (ICD) patients
(short-term observed and long-term fitted), anti-arrhythmic drugs (AAD) patients (long-term fitted) and general
population (observed) using the Weibull, Cox-like, poly-Weibull and poly-Gompertz models.
sex. While Demiris and Sharples [6] assumed proportional hazards for all causes of death between the
ICD cohort and the general age–sex matched population, we assume that the ICD patients have (higher)
proportional hazards for arrhythmic deaths, but identical mortality for other causes of death, compared
to the population.
The UK population survival data were generated using annual life tables, by age and sex, pub-
lished by the UKOffice for National Statistics (ONS) (http://www.ons.gov.uk/ons/taxonomy/index.html?
nscl=Interim+Life+Tablesdownloaded16thDec2012). We also obtain population data on causes of death
from the UK ONS, in particular their table of deaths by underlying cause, for diseases of the circulatory
system. In an informal discussion with a clinical expert (Andrew Grace, personal communication), we
identified which coded causes of death in this table were thought to be arrhythmia related, thus potentially
preventable by ICD implantation. Hence, we computed the proportion of deaths, which were related to
arrhythmia, illustrated in Figure 6 for sex and 5-year age groups. For each ICD patient, we generated
survival times from 20 controls from the general population, matched by age and sex. The survival time
for each control was generated by randomly sampling their annual survival status, year by year, using the
survival probabilities from the published life tables. A cause of death (classified as arrhythmia or non-
arrhythmia) was similarly generated for each control by random sampling using the data in Figure 6.
Twenty controls were judged to be sufficiently many that we can assume negligible sampling uncertainty
in the population data relative to the study data.
Note that over the age range of interest (⩾ 60 years), the proportion of deaths (potentially) related
to arrhythmia is fairly constant for men but is increasing for women (Figure 6). This suggests that
assuming proportional all-cause hazards may give greater biases for women than men in extrapolated
survival estimates.
4.2. Models for combining cohort and population data
In previous sections, we extrapolated the survival of a single group of patients at high risk of death from
a specific cause, using population survival patterns. We do this here for the ICD cohort using the previ-
ously described models: a Weibull with proportional all-cause hazards between the ICD cohort and the
population data, a Bayesian semi-parametric Cox-like model, and a poly-Weibull model with propor-
tional hazards for arrhythmia mortality. The same prior distributions were used as in the simulation study
(Section 3.2). As a test of theWeibull assumption for cause-specific hazards, we fitted an alternative poly-
hazard model based on the Gompertz distribution. This ‘poly-Gompertz’ model has the same definition
as in Equation (2), but with cause k hazard 𝜆k exp(𝛼kt) instead of 𝜆k𝛼kt𝛼k−1, so that we again assume pro-
portional cause-specific hazards, but with a differently shaped hazard trajectory. Similar principles were
used to derive its priors.
4.3. Comparisons between competing treatments
In cost-effectiveness analysis, we typically need to compare expected survival between patients receiving
different interventions. Thus, we add a third data source to our ICD patients and our general population.
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Figure 6. Proportion of deaths in the UK population in 2002, which were due to cardiac arrhythmia
In this example, we compare patients implanted with ICDs to patients treated with AAD. A summary
treatment effect is available from a meta-analysis of three randomised controlled trials [5] comparing
ICDs with AAD for the secondary prevention of sudden cardiac death. For the outcome of death from any
cause, the hazard ratio (ICD : AAD) was 0.72 (95% CI: 0.60–0.87). For death from arrhythmia-related
causes, the published hazard ratio was 0.50 (95% CI: 0.37– 0.67). We can incorporate this information
straightforwardly in our previous models as a prior distribution, assuming only the hazard related to
arrhythmia deaths is affected by the treatment. Thus, using the notation of Section 2, the hazards for the
population, ICD and AAD groups under the polyhazard models are, respectively, given by
hp(t|𝛼, 𝜆) = h1p(t|𝛼1, 𝜆1) + h2p(t|𝛼2, 𝜆2)
hs(t|𝛼, 𝜆, 𝛽) = e𝛽h1p(t|𝛼1, 𝜆1) + h2p(t|𝛼2, 𝜆2)
hAAD(t|𝛼, 𝜆, 𝛽, 𝛾) = e𝛾+𝛽h1p(t|𝛼1, 𝜆1) + h2p(t|𝛼2, 𝜆2),
(5)
where 𝛾 is the log hazard ratio (AAD : ICD) related to arrhythmia-related deaths. Using themeta-analysis
summary statistic given in the preceding text, we set the prior for this parameter to be N(0.693, 0.1482).
For the Weibull and Cox-like models, which assume proportional overall hazards, we have population
hazard hp(t|𝜆, 𝛼), and
hs(t|𝜆, 𝛼, 𝛽) = e𝛽hp(t|𝜆, 𝛼)
hAAD(t|𝜆, 𝛼, 𝛽, 𝛾) = e𝛽+𝛾hp(t|𝜆, 𝛼),
where 𝛾 here is the log hazard ratio (AAD : ICD) related to all causes of death. For these models, the
prior for 𝛾 was N(0.3285, 0.0932), also obtained from the meta-analysis summary hazard ratio.
The outcome of interest is the life years gained (LYG) from a policy of ICD implantation compared to
AAD treatment, which is the difference between the expected survival for patients under each treatment.
These are presented in Table 5, and the estimates for the basic parameters are given in Table 5 of the
online Appendix B.
4.4. Comparison of model fit
The poly-Weibull distribution fits the ICD study data reasonably well overall (Figure 5), and by gen-
der (Supplementary Figure 7). Supplementary Figure 8 indicates that the Weibull distribution gives an
adequate fit to the general population survival data by cause and gender. This suggests the poly-Weibull-
based model is reasonable for use in extrapolation. The estimates of the survival of ICD patients from the
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other three models agree with the Kaplan–Meier estimate well. Although note that short-term fit is only
a limited guide to long-term model adequacy—the poly-Gompertz models show substantially poorer fit
to the long-term general population data for both arrhythmic and non-arrhythmic death times separately
and both genders (Figure 8). Figure 5 also suggests the hazard over 40 years is underestimated (or sur-
vival overestimated) by the poly-Gompertz model due to the influence of the data from the first 5 years
on the shape of the trajectory.
The polyhazard models are of identical complexity, so improvements in fit can be quantified by reduc-
tions in the posterior mean deviance D corresponding to likelihood contributions (1) (for each cause
of death separately) and (3). While D for the study data is 16 lower for the poly-Gompertz model
compared to the poly-Weibull, the correspondingD for long-term general population arrhythmic and non-
arrhythmic deaths is 270 and 98 higher, respectively, indicating a poorer overall fit for the poly-Gompertz.
This suggests the poly-Gompertz would give less plausible extrapolations of long-term survival of our
study patients, despite the marginally better short-term fit.
4.5. Comparison of expected survival
The estimated LYG is greater by more than 1 year under the poly-Weibull model, compared to the two
models that ignore causes of death (Table IV). This difference between the models is most apparent in
the estimated survival for the AAD patients, which is also influenced by the meta-analysis through the
parameter 𝛾 . These results are also demonstrated in Figure 5, which shows the fitted survival curves and
log hazards for both the ICD and AAD patients. The poly-Gompertz gives much higher estimates of
expected survival and LYG, and its poorer fit to the long-term data suggests that these are implausible.
Under the Cox-like model, the expected survival for both the treatment groups is greater compared to the
Weibull, but the incremental survival is not materially affected—this suggests that modelling the baseline
survival more flexibly does not completely alleviate bias due to ignoring cause-specific mortality.
Recall that the priors were weakly informative and based on beliefs expressed on a natural
scale (Section 3.2). The results were found to be robust to alternative standard choices, except in the case
of the polyhazard models for women, where the mean survival was sensitive to the assumed prior vari-
ance, because these models are weakly identifiable given there are only 104 women in the ICD data, 12 of
whom died. For example, in the poly-Weibull, the mean ICD survival for women was 11.13 under a N(0,
1000) prior for the log(𝜆k), which is effectively uniform on a different scale although permits unnaturally
high survival times.
As previously noted, Figure 6 shows that the proportion of deaths by age for men that are due to
arrhythmia is approximately constant from age 60 years, but increases with age for women. Because of
this, the effect of treatment might differ by gender (see application in Section 4). The expected survival
and LYG for each gender individually are presented in Table IV. Again, the LYG are greater for both men
Table IV. Posterior mean (posterior standard deviation) of expected survival
for patients receiving implantable cardioverter defibrillators (ICDs) and anti-
arrhythmic drugs (AAD), by sex.
Survival models
Parameter Weibull Cox-like Poly-Weibull Poly-Gompertz
Overall
ICD mean survival 8.88 (0.71) 9.41 (0.78) 9.18 (0.75) 11.54 (1.03)
AAD mean survival 7.06 (0.73) 7.43 (0.81) 6.06 (0.80) 7.62 (1.15)
Life years gained 1.82 (0.49) 1.98 (0.53) 3.12 (0.61) 3.92 (0.78)
Male
ICD mean survival 8.52 (0.73) 9.04 (0.81) 8.72 (0.75) 11.00 (1.03)
AAD mean survival 6.79 (0.73) 7.13 (0.82) 5.80 (0.78) 7.31 (1.14)
Life years gained 1.73 (0.47) 1.91 (0.52) 2.91 (0.58) 3.69 (0.74)
Female
ICD mean survival 10.11 (1.95) 9.87 (2.14) 9.96 (1.97) 14.54 (3.25)
AAD mean survival 8.22 (1.66) 7.92 (1.81) 6.85 (1.61) 9.87 (3.14)
Life years gained 1.89 (0.62) 1.95 (0.65) 3.11 (0.76) 4.67 (1.05)
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and women if assuming a cause specific rather than an overall mortality differential between the general
and study populations. For women, this difference is approximately 65% higher, which implies that in a
cost-effectiveness analysis, the cost per year of life gained would be almost 60% of that estimated by the
models that ignore causes of death. However, even for men, there is a difference of about a year between
the estimated survival of AAD patients after accounting for cause-specific mortality. Interpretation of
the results in this particular example is not straightforward. The overall mean survival for both men
and women is similar for the Weibull, Cox-like and poly-Weibull models, which was expected for men
but not for women. Failure to identify the increasing proportion of deaths attributable to arrhythmias in
women may be due to the small sample in the ICD cohort (12 deaths in 104 women), which may have
caused identification problems in the poly-Weibull model. Sensitivity to prior distributions highlighted
in the preceding text is also an indication of the lack of information in this data set. In this example,
the increase in LYG for both men and women in the cause-specific analysis results from the difference
in estimated mean survival for the AAD patients, which is driven by both the published arrhythmia-
specific hazard ratio and the proportion of all cause mortality that can be influenced by an ICD. Reliable
analysis will depend on correct classification of the causes of death that can be influenced by the ICD
and an estimate of the arrhythmia-specific hazard ratio 𝛾 that is consistent with these causes. The large
difference between the Poly-Weibull and Weibull observed in this example may be due to inconsistency
in the definition of ‘arrhythmic mortality’ between the cause-specific hazard ratios published by Connolly
et al. [5] and our clinical colleague’s informal identification of arrhythmia-related causes of death in the
general population—thus, the model may not be adjusting for the difference between the population and
study patients properly.
4.6. Sensitivity to classification of causes of death
To investigate this potential misclassification, we performed two sensitivity analyses, in which we
randomly reclassified 10% and 20% of the arrhythmia-coded deaths in the general population as non-
arrhythmic, and fitted the poly-Weibull model again. This resulted in reductions in the expected survival
of both treatment groups, and a 4% and 8% reduction in the expected LYG from ICD, respectively, (Table
6 of the online Appendix B). This is as expected, because with fewer deaths in the long term, which might
have been affected by the treatment, the effect of treatment on extrapolated survival will be lower. The
same reductions in expected LYG are observed for the same analyses by gender. However, the estimated
survival of male AAD patients is still about a year lower after accounting for cause-specific mortality
using the poly-Weibull.
Another possible explanation is that the ICD study cohort may be at greater risk than the general
population from other causes of death in addition to arrhythmia. Labelling these causes ‘cause 3’ (and
omitting the parameters 𝛼, 𝜆 on the right-hand side for clarity), the population survival in Equation (5)
would become
hp(t|𝛼, 𝜆) = h1p(t) + h3p(t) + h2p(t).
The parameter 𝛽 would then represent the log hazard ratio between the population and cohort for these
causes combined with arrhythmia, so that
hs(t|𝛼, 𝜆, 𝛽) = e𝛽{h1p(t) + h3p(t)} + h2p(t).
However, assuming the published effect 𝛾 of treatment (AAD or ICD) only applies to cause 1 mortality,
the true hazard for the AAD group would then be
hAAD(t|𝛼, 𝜆, 𝛽, 𝛾) = e𝛾+𝛽h1p(t) + e𝛽h3p(t) + h2p(t).
In order for our previous model (5) to apply in this situation, with h1p(t) replaced by h
1
p(t)+h
3
p(t), 𝛾 would
need to represent the effect of treatment on causes 1 and 3 combined, which would be weaker than the
published arrhythmia-specific effect. Because the AAD group has poorer survival, this would explain the
possible underestimation of the AAD-specific survival in the poly-Weibull model.
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5. Discussion
Extrapolations of survival of patients from randomised trials or study cohorts can often be facilitated
with official survival statistics from the general population. This requires carefully characterising the
differences between the population and the study patients. We have examined the circumstances under
which simply assuming proportional hazards for all-cause mortality can lead to bias when estimating
expected lifetime survival. If the study patients are at a higher risk of death from some identifiable cause,
and the contribution of that cause to overall mortality is not constant through time, then the hazards
for overall mortality will not be proportional. The resulting bias can be alleviated by using proportional
hazards for the cause of interest, assuming that cause-specific survival times are available in either the
population or the study data. If causes of death are unpublished in just one of the two datasets, as in
our example, then overall survival in that dataset can be modelled with a polyhazard distribution, whose
hazard is defined as the sum of cause-specific hazards.
In our application to ICD, ignoring the cause-specific hazard ratio resulted in a lower estimate of the
gain inmean survival for women, for whom the proportion of deaths due to arrhythmia increases with age.
The corresponding LYG from ICD implantation as compared to AAD was approximately 65% higher
after accounting for cause-specific survival. Hence, the cost per life year gained, required for policy-
making, would be substantially higher under the Weibull model, which is likely to be misspecified. Care
should be taken in the interpretation of these estimates, because the size and direction of bias will be
influenced both by the varying proportion of arrhythmia deaths and by other model assumptions, such as
the fit of the Weibull model, the accuracy of the classification of causes of death, and the assumption that
the causes that distinguish the ‘arrhythmia’ cohort from the population are the same causes affected by the
published ‘arrhythmia-specific’ treatment effect. In the ICD example, both men and women ICD patients
had lower estimated gain in survival time compared to AAD patients using theWeibull model (Table IV),
despite the largely constant proportion of deaths classified as arrhythmia related (Figure 6). It is possible
that assumptions regarding the classification of causes of death and the partitioning of the overall hazard
into cause-specific hazards influenced these estimates of survival, as discussed in the previous section,
particularly because they are extrapolated. It is difficult to distinguish the effect of each questionable
assumption in extrapolation. This emphasises the need for sensitivity analyses, and careful and consistent
categorisation of causes of death in survival data. In addition, a more comprehensive simulation study,
including a wider range of survival distributions and patterns of risk contributions, would clarify the
extent of potential bias and efficiency resulting from ignoring cause-specific hazards.
The Weibull distribution is particularly convenient for modelling cause-specific survival because its
proportional hazards property gives an intuitive scale for expressing the differences between populations,
and treatment effects are typically published as hazard ratios. However, the Weibull family has a limited
range of hazard trajectories, which may not express, for example, the rapidly increasing hazards seen in
older populations. Different distributions can be used to generate polyhazard models. The Gompertz was
investigated in our application, although found to be less suitable for our data. A semi-parametric Cox-
type model with competing hazards would allow a more flexible baseline hazard for describing general
population survival patterns, although any assumptions about proportionality of hazards should still be
checked. Our simulation also suggested that bias can be alleviated by using a semi-parametric model,
while still assuming proportional overall hazards, but at the cost of reduced precision compared to using
the true parametric survival distribution. In addition, our poly-Weibull formulation assumes that hazards
for different causes are additive and independent of each other, an assumption that is again impossible to
test and may require sensitivity analysis.
As in any Bayesian application, priors may be influential for smaller sample sizes and models with
more parameters. If substantive prior knowledge exists, as it does for human survival, it should be
included. In our example, expected survival for women appeared to be overestimated by a year under
an unrestricted diffuse prior, which placed about 50% prior mass on mean survival times of more than
1000 years.
If the interest is in comparing expected survival between different interventions, then the intervention
effect will typically be only available from randomised trials with short-term follow-up. Comparing sur-
vival over longer periods requires untestable assumptions, such as the treatment effect remaining constant
after the end of the trial, or instantly reducing to zero, or decreasing gradually through time. Again, these
can only be explored through sensitivity analysis. Note also that the example we present involves a joint
analysis of randomised data, included as a prior on an intervention effect 𝛾 , and observational data. The
posterior distribution of the intervention effect is however identical to the prior, because the observational
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data do not contribute any likelihood. 𝛾 can therefore be interpreted as a causal effect of the randomised
intervention. In other examples, we might want to estimate 𝛾 from a combination of randomised and
observational data. Then for a causal interpretation, we must ensure, for example, that all confounders
have been controlled for.
Finally, it is important to bear in mind the context in which these issues arise. Survival patterns in
different subgroups are almost invariably a feature of health economic decision models, but other primary
and secondary data sources are often included. In particular, disease progression and its relationship with
survival is typically modelled, along with costs and utility assessments associated with different health
states. The relationship between cause-specific survival methods and other components of the decision
model should be the subject of future work.
Appendix A: WinBUGS model code
Here, we present the code for both the two-component poly-Weibull model, discussed in Section 2, and
a Weibull model, which ignores the cause specific effect.
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